Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: Strategies, clinical outcomes, and costs at 2 years

European Journal of Ophthalmology

Volumn 15, Issue 5, 2005, Pages 562-580

  Rouland, Jean François ^a   Le Pen, C ^b,c,e   Benhaddi, H ^c,e   Piriou, E ^e   Lilliu, H ^d,e   Kenigsberg, P A ^d  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ PARIS DAUPHINE   (France)

^c Aremis Consultants   (France)

^d PFIZER INC   (United States)

^e CLP Sante   (France)

Author keywords

Adverse drug reactions; Costs; IOP; Ocular hypertension; Persistency; Primary open angle glaucoma; Treatment strategy

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRIMONIDINE; CARBONATE DEHYDRATASE INHIBITOR; LATANOPROST; TIMOLOL;

ADULT; AGED; ARTICLE; DRUG COST; DRUG SAFETY; FEMALE; FOLLOW UP; FRANCE; HEALTH CARE COST; HEART DISEASE; HUMAN; INTRAOCULAR HYPERTENSION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN ANGLE GLAUCOMA; OPTIC NERVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

EID: 26444491100     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210501500507     Document Type: Article

References (34)

1. Rapport du Groupe Technique National de Définition des Objectifs: élaboration de la loi relative à la politique de santé publique. Available at: http://www.sante.gouv.fr/htm/dossiers/losp/accueil.htm. Accessed March 27, 2003.
2. European Glaucoma Society. Principes du traitement et options thérapeutiques. In: Guide pour les Glaucomes. Savona, DOGMA® S.r.l.; 1999: 81-110.
3. Alward WLM. Medical management of glaucoma. N Engl J Med 1998; 339: 1298-307.
4. Haut Comité de la Santé Publique. Données et résultats. In: la Santé en France 2002, Paris, Paris: La Documentation Française; 2002: 157-9.
5. Palmberg P. Answers from the ocular hypertension treatment study. Arch Ophthalmol 2002; 120: 829-30.
6. The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000; 130: 429-40.
7. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998; 126: 487-97.
8. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol 1998; 126: 498-505.
9. Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991; 111: 51-5.
10. Weinreb RN, Friedman DS, Fechtner RD, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004; 138: 458-67.
11. Gordon MO, Beiser JA, Brandt JD, et al. The ocular hypertension study. Baseline factors that predict the onset of primary-angle glaucoma. Arch Ophthalmol 2002; 120: 717-20.
12. Kass MA, Heuer DK, Higginbotham EJ, et al. The ocular hypertension treatment study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13.
13. Bateman DN, Clark R, Azuara-Blanco A, Bain M, Forrest J. The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care. Br J Ophthalmol 2002; 86: 551-5.
14. Bateman DN, Clark R, Azuara-Blanco A, Bain M, Forrest J. The impact of new drugs on management of glaucoma in Scotland: observational study. Br Med J 2001; 323: 1401-2.
15. Paikal D, Yu F, Coleman AL. Trends in glaucoma surgery incidence and reimbursement for physician services in the Medicare population from 1995 to 1998. Ophthalmology 2002; 109: 1372-6.
16. Baudouin C, Bȩchetoille A, Bron A, et al. Intȩrêt de la mesure de la qualitȩ de vie et de l'observance thȩrapeutique chez les patients atteints de glaucome chronique à angle ouvert. J Fr Ophtalmol 2000; 23: 1057-64.
17. Alm A, Stjernschantz J, the Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Ophthalmology 1995; 102: 1743-52.
18. Camras CB, the United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A six-month, masked, multicenter trial in the United States. Ophthalmology 1996; 103: 138-47.
19. Watson P, Stjernschantz J, the Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996; 103: 126-37.
20. Zhang WY, Po AL, Dua HS, Azuara-Blanco A. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol 2001; 85: 983-90.
21. Site officiel du Programme de Mȩdicalisation des Systèmes d'information (PMSI). Available at: www.atih. sante.fr/pmsi. Accessed January 15, 2003.
22. Rouland JF, Peignȩ G, Sellem E, et al. Etude observationnelle rétrospective de coûts des deux premières années de traitement dans le glaucome primitif à angle ouvert et l'hypertension oculaire en France. J Fr Ophtalmol 2001; 24: 233-43.
23. Briggs AH, Gray AM. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technology Assessment 1999; 3: 1-144.
24. Fiscella RG, Geller JL, Gryz LL, Wilensky J, Viana M. Cost considerations of medical therapy for glaucoma. Am J Ophthalmol 1999; 128: 426-33.
25. Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 2002; 8 (Suppl): S271-7.
26. Spooner JJ, Bullano MF, Ikeda LI, et al. Rates of discontinuation and change of glaucoma therapy in a managed care setting. Am J Manag Care 2002; 8 (Suppl): S262-70.
27. Dasgupta S, Oates V, Bookhart BK, Vaziri B, Schwartz GF, Mozaffari E. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care 2002; 8 (Suppl): S255-61.
28. Rouland JF, Le Pen C, the ophthalmologists of the Glaucoma Study. Naturalistic, prospective study of glaucoma and ocular hypertension treatment in France: strategies, clinical outcomes and costs at 1 year. Eur J Ophthalmol 2003; 13 (Suppl): S5-20.
29. Diestelhorst M, Schaefer CP, Beusterien KM, et al. Persistency and clinical outcomes associated with latanoprost and beta-blocker monotherapy: evidence from a European retrospective cohort study. Eur J Ophthalmol 2003; 13 (Suppl): S21-9.
30. Bernard LM, Althin R, Dhawan R, Grima DT, Lam A, Aballea S. Clinical and economic impacts of latanoprost 0.005% in first-line treatment of open-angle glaucoma and ocular hypertension in France. Eur J Ophthalmol 2003; 13 (Suppl): S30-43.
31. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol 2003; 13 (Suppl): S44-52.
32. Kobelt G, Jönsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in Germany. Graefes Arch Clin Exp Ophthalmol 1998; 236: 811-21.
33. Fiscella RG. Costs of glaucoma medications. Am J Heath Syst Pharm 1998; 55: 272-5.
34. Rouland J-F, Hågå A, Bengtsson S, Hedman K, Kobelt G. What triggers change of therapy? In: Jönsson B, Krieglstein G, eds. Primary Open-angle Glaucoma: Differences in International Treatment Patterns and Costs. Oxford, U: Isis Medical Media Ltd.; 1999: 163-9.